Hiki ke hoʻoholo ʻia kāu ʻikepili Phosphoproteomics ma mua o ka unuhi ʻana

Pane wikiwiki

A pre-analytical control framework for phosphopeptide workflows connecting fixation timing, cold-chain handling, phosphatase inhibitor selection, enrichment pa…

Kahi e hele hewa ai ka hōʻailona Phosphorylation

He haʻahaʻa loa ka Phosphorylation stoichiometry. I kēlā me kēia manawa, ʻO kahi hapa wale nō o ka pūnāwai o ka protein target e lawe i kahi hanana phosphorylation kikoʻī, a mālama ʻia kēlā hakina e nā hana kūʻē o nā kinases a me nā phosphatases. As a 2015 loiloi ma Molecular BioSystems hōʻuluʻulu ʻia, nā pilikia e pili ana i ka phosphoproteomics - haʻahaʻa stoichiometry, nalo phosphopeptide ma waena o ka hoʻomākaukau ʻana i nā pae he nui, impaired ionization pono, a me ka localization phosphosite pololei - ua hui pū ʻia nā mea a pau ke mālama ʻole ʻia nā mea hoʻololi pre-analytical.

ʻAʻole hoʻomaha ka Phosphatases ke kau ʻia kahi laʻana i loko o kahi paipu. Ma ka mahana wela, Ke hoʻomau nei ka dephosphorylation enzymatic ma o ka lysis, dilution, a ʻo ka hoʻomaka mua ʻana o ka denaturation protein ke ʻole nā ​​​​hana kikoʻī e hoʻopau ai. No ka tyrosine phosphorylation, ua kākau maikaʻi ʻia ka hopena ma ka palapala mua: i ka hoʻomākaukau ʻana o ka membrane T-cell kaʻawale, ka wehe ʻana i ka protein-tyrosine-phosphatase inhibitor i hana ʻia e Lck, ʻO Fyn, ʻO Syk, Zap70, a me CD3ζ e lilo dephosphorylated wikiwiki, a me ka tyrosine phosphorylation o β- a ʻo nā γ-catenins Hoʻopau loa ʻia e ka mālama ʻana i ka phosphatase i ka wā i ʻole ai ka inhibitor. A 2019 ʻano loiloi ʻike e hiki ke hāʻule ka hōʻailona phosphopeptide me ka ʻole o ka phosphatase inhibitor a piʻi pū me ia, a paipai i ka holo ʻana i nā laʻana me ka ʻole a me ka mea hoʻopaneʻe i ka wā e hoʻāʻo ai i ka tyrosine phosphorylation. ʻO ka nui o ka poho pili i ka pōʻaiapili - ʻokoʻa ia me ka protein, kikokiko, mahana wela, a lohi ma mua o ke kinai ʻana - no laila ʻaʻole pono e hoʻemi ʻia i hoʻokahi pākēneka honua. ʻO ka hopena kūpono: inā ʻaʻole i hoʻolālā ʻia kahi protocol hoʻohana ʻana e hopu i ka hana enzymatic me ka wikiwiki a piha, ʻO ka phosphoproteome āu e ana ʻaʻole hōʻike i ka biology āu i manaʻo ai e aʻo a i ʻole kahi mea hana like ʻole - hōʻike ia i kahi hui ʻole o nā mea ʻelua..

Hiki ke hoʻoholo ʻia kāu ʻikepili Phosphoproteomics ma mua o ka unuhi ʻana

Nā kumu hoʻohālikelike mua o ka hui ʻokoʻa i ʻelima mau ʻanuʻu hiki ke hoʻopaʻa ʻia: hoʻopaʻa manawa, aʻo kaulahao anu, haku mele lysis, hoʻokō waiwai, a me LC-MS kaʻina hana. Ka hoʻomalu ʻana i kēlā me kēia pae ma ke kaʻawale, a laila hoʻoponopono iā lākou ma ke ʻano he ʻōnaehana, ʻO ia ka wehewehe hana o ka pre-analytical rigor i ka phosphoproteomics.


ʻO ka manawa hoʻoponopono a me ka Ischemia Cold: Hoʻomaka ka uaki ma ka wehe ʻana

No ka phosphoproteomic ma muli o ke kino, ʻo ka wā ma waena o ka wehe ʻana a me ka hoʻoponopono ʻana - i kapa ʻia ʻo ka manawa ischemic maʻamau - ʻo ia ka mea hoʻokahi o ka hopena pre-analytical variable.. A 2013 Nūpepa no ka Proteome Research ao ana Ua nānā ʻia nā ʻiʻo ʻiole a me ka ʻiole i hoʻoponopono ʻia me nā lōʻihi o ka ischemia anuanu a hoʻoholo i ka hoʻolōʻihi ʻana i ka "hoʻololi phosphoproteome ʻaʻole hiki ke wānana a ʻaʻole i hāʻawi ʻia i nā protein pilikino." ʻAʻole kēia he hopena marginal ma kahi liʻiliʻi o nā pūnaewele; ʻo ia ka hāʻawi hou ʻana o ka hōʻailona phosphorylation e hoʻolaha ana ma kēlā me kēia kaʻina loiloi iho.

Hoʻopiʻi hou ka laina manawa ma ka pae pūnaewele. A 2014 Imi Keena Hana ao ana ka helu ʻana i ka hōʻike phosphoepitope i loko o ka ʻiʻo FFPE i ʻike ʻia ua emi ka hōʻailona epitope phosphorylated i ka hoʻonui ʻana i ka manawa-i-fixation., me kekahi mau epitopes e hōʻike ana i ka pohō i loko 30 mau minuke o ka ischemia anu. ʻO kahi ma hope 2021 PMC ke aʻo ʻana e pili ana i ka ischemia maʻamau i ka ʻiʻo tumor hoʻoikaika i ke kiko, me ka ʻike ʻana ʻaʻole kūpono nā mea FFPE no ka hoʻāʻo ʻana i ka hana kinase a i ʻole ka nānā ʻana i ka phosphostatus ke mālama ʻole ʻia ka ischemia anuanu..

ʻElua mau hoʻoholo kūpono ma muli o kēia hōʻike:

Koho waiwai: ʻOi aku ka maikaʻi o ka mālama ʻana i ka pono o ka phosphoproteome ma mua o ka FFPE no ka loaʻa ʻana o ka phosphoproteomic.. Hiki i nā kahe hana FFPE ke hana no ka nānā ʻana i ka phosphoepitope i manaʻo ʻia me nā antibodies i hoʻopaʻa ʻia a i ʻole ka nānā ʻana i ka hopena, akā aia wale nō ke kākau ʻia ka protocol fixation a me ka manawa ischemia anuanu a i loko o nā palena i hōʻoia ʻia.

Pono palapala: Pono e mālama ʻia ka manawa ischemia ma ke ʻano he covariate hoʻokolohua koi, ʻaʻole he hōʻike hoʻomalu. Inā ʻaʻole hiki ke hoʻohālikelike i nā hui hoʻohālikelike, pono e hoʻohālike ʻia e like me ka huikau ma mua o ka nānā ʻole ʻia.

ʻIke kiko: ʻO ka palapala anu-ischemia ma luna aʻe i loaʻa mua mai i nā ʻano hoʻohālike o ke ake koʻikoʻi a me ka ʻiʻo ʻiʻo; ʻO ka nui a me ka wikiwiki o ka phosphoproteome drift he matrix- a pili i nā ʻano, no laila e mālama ʻia nā paepae ma lalo nei e like me nā wahi hoʻomaka e hōʻoia hou ʻia no kēlā me kēia ʻano kikoʻī ma mua o nā mea mau..

Kuhikuhi manao: Ua hoʻopuka ke kahua i ke alakaʻi hōʻike liʻiliʻi no ka hoʻomākaukau ʻana o ka laʻana phosphoproteomics ma lalo o ka ʻIke liʻiliʻi e pili ana i ka hoʻomākaukau ʻana i nā laʻana no Phosphoproteomics papa hana, a me nā loiloi biospecimen lāʻau lapaʻau e ʻōlelo ʻia e kaupalena ʻia ka ischemia anu i lalo 30 mau minuke no nā noi phosphoproteomic. ʻO ka hoʻolikelike ʻana i kāu SOP me kēia mau kūlana kaiāulu e hoʻohālikelike pololei i nā ʻano hana ma waena o nā laboratories.


ʻO ka hoʻopaʻi hoʻopaʻa ʻana me ka Lysis Buffer Design

Ma waho o ka hoʻoponopono, ʻO kēlā me kēia ʻanuʻu mai ka hōʻiliʻili laʻana ma o ka denaturation protein e lawe i ka pilikia enzymatic. ʻO ka hoʻohaʻahaʻa kūpono ʻo ia ka hoʻomalu ʻana i ka wela i hui pū ʻia me ka hopu kemika.

ʻO kahi phosphoproteomic maʻamau loiloi ʻia ka protocol ma PMC kuhikuhi i ka hau a i ʻole 4°C ka hana ʻana no nā ʻanuʻu āpau ma mua o ka lysis a paipai i ka mālama ʻana o −80 °C no nā pellet cell inā ʻaʻole hiki ke unuhi koke ʻia.. ʻAʻole kēia mau koho conservative; he mau koi ukana. Pumehana ma ka centrifugation, nā hoʻoili ʻana o ka paipu wela lumi, a i ʻole nā ​​lohi ma waena o nā ʻanuʻu hōʻiliʻili ua lawa kēlā me kēia e hoʻokomo i nā loli phosphorylation hiki ke ana inā ʻaʻole i hoʻopaʻa ʻia ka hana enzymatic..

ʻO ke koho ʻana i ka Phosphatase Inhibitor

ʻO ka hoʻohui ʻana i ka phosphatase inhibitors i ka lysis buffer ʻo ia ka hoʻolālā hoʻopaʻa paʻa kemika, akā, ʻaʻole ia he mea koʻikoʻi ke koho ʻana i ka mea hoʻokae. As Olsen et al. ʻike ʻia i kā lākou loiloi PMC o nā ʻenehana hoʻonui, ʻO ka hoʻokomo ʻana i nā mea pale protease a me ka phosphatase i loko o nā mea hoʻoheheʻe e pono pinepine ai, a ʻo kēlā me kēia inhibitor phosphatase he kikoʻī kūʻokoʻa. ʻO ka sodium fluoride ka mea e kāohi ai i ka serine/threonine phosphatases; ʻO ka sodium orthovanadate ka mea maʻamau no ka tyrosine phosphatases; Hoʻopuka ka β-glycerophosphate i kahi ākea ākea o nā serine/threonine phosphatases me kahi moʻolelo hoʻohālikelike MS ʻoi aku ka maikaʻi ma mua o ka fluoride.. ʻO ka hoʻohana ʻana i kahi mea paʻa hoʻokahi e uhi i ke kiko piha o ka hana phosphatase he kumu mahalo ʻole ʻia o ka pae kikoʻī kikoʻī - e hōʻike ʻole ʻia kekahi mau ʻāpana phosphoproteome inā loaʻa nā hakahaka..

Hoʻohuihui Peptide ʻO ka cocktails inhibitor Phosphatase i hoʻokumu ʻia no ka phosphoproteomics (e.g., PhosSTOP a i ʻole nā ​​hui like) ʻoi aku ka maikaʻi ma mua o nā hoʻokokoke hoʻokahi no nā kahe hana ʻike. No nā kaʻina hana i manaʻo ʻia e pili ana i nā node hōʻailona kikoʻī, Hiki ke hoʻopololei ʻia ke koho inhibitor a puni nā ʻohana phosphatase pili loa i ka biology e aʻo ʻia.

⚠️ ʻŌlelo Aʻo: Wehe i ka phosphatase inhibitors ma mua o ka proteolytic digestion. ʻO kekahi mau mea hoʻopaneʻe maʻamau - ʻoi aku ka sodium fluoride - ke keʻakeʻa i ka hana trypsin, e hōʻemi ana i ka uhi ʻana o ka peptide a me ka hoʻokomo ʻana i ke kaʻina digestion e pili ana i ke kaʻina. A 2021 PMC e aʻo i ka hoʻomākaukau laʻana phosphoproteomics e hōʻoia ana i ka lawe ʻana o ka phosphatase inhibitor i loko o ke kaʻina hoʻoheheʻe e hōʻemi i ka helu o nā phosphopeptides i ʻike ʻia.

ʻO ka Denaturing Lysis ma ke ʻano he koho

No nā ʻano laʻana i lawa ʻole ka hopu ʻana i ka enzymatic - ʻoi aku ka nui o nā paʻakikī protein a i ʻole ka pono o ka organelle e lohi i ke komo ʻana i ka mea hoʻopaneʻe - denaturing i nā kūlana lysis (8 M urea, a i ʻole SDS-based lysis i ukali ʻia e ka wehe ʻana i ka mea holoi) hāʻawi i kahi hoʻolālā hoʻopaʻa orthogonal. Hoʻopau ka denaturation wikiwiki i ka hana enzymatic ma mua o ka hoʻokokoke ʻana i ka inhibitor, i ke kumukūʻai o ka hoʻonui ʻana i ka paʻakikī o ka hoʻoili ʻana i lalo no ka wehe ʻana i ka detergent. No nā hoʻokolohua laina kelepona kahi e hopu ʻia ai ka mokuʻāina phosphoproteome ma kahi hopena hoʻoikaika pololei, ʻO ka denaturing lysis ke koho ʻoi aku ka hilinaʻi kiʻekiʻe.


Hoʻopili ʻia nā kuʻina hoʻokūpaʻa i ka laʻana matrix

ʻAʻole like nā mea hoʻololi pre-analytical ma nā ʻano laʻana. Hōʻike ka papa ma lalo i ka hana koʻikoʻi e ka matrix, me nā koina ʻae no kēlā me kēia:

Laʻana ʻO nā Peptides Synthetic Matrix

Kiʻi Pre-Analytical Risk

Manaʻo ʻia ʻo Intervention

Palapala ʻae

Pūnaehana moʻomeheu (pili)

Enzymatic drift i ka wā trypsinization / ka wehe ʻana i ka media

E kinai pololei ma luna o ka pā me ka hau-anu PBS + mea hoʻopaneʻe; aspirate a lyse koke

Ka manawa mai ke kinai a hiki i ka lysis ≤ 5 min; mālama ʻia ka pellet ma −80°C inā ʻaʻole i hana ʻia i ka lā hoʻokahi

Pūnaehana moʻomeheu (hoʻopaneʻe)

Hoʻopaneʻe ka pelleting ma kahi mahana

Centrifuge ma 4°C koke; wehe i ka supernatant ma ka hau; uila-paʻa pellet

ʻAʻole ʻoi aku ka mahana o ka pellet ma mua o 4 ° C i kēlā me kēia manawa; maloʻo i loko 10 min o ka centrifuge stop

Koko (PBMC kaawale)

Hoʻololi ka lohi kaʻina hana i ka phosphoprofile

E hoʻomaka i ka hoʻokaʻawale PBMC i loko 2 hola huki; e hoʻohui i nā mea paʻa ma mua o ka hoʻokaʻawale ʻana

≤ 2 h lohi; manawa hoʻopaneʻe palapala no kēlā me kēia paipu

ʻO ka biopsy pūnaewele (hou)

Ischemia anu

Snap-freeze i loko o ka wai nitrogen 20 min o ka resection; palapala manawa ischemia

Ischemia anu ≤ 20 min; hoʻokaʻawale i hōʻailona ʻia ma ke ʻano he covariate

ʻiʻo FFPE

ʻO ka maikaʻi o ka hoʻoponopono a me ka manawa ischemia

E hoʻohana i nā laʻana wale nō me ka ischemia i kākau ʻia < 30 min a me ka hoʻolaha formalin 6-24 h

Hoʻokaʻawale a hoʻokaʻawale paha i nā laʻana āpau me ka manawa hoʻopaʻa palapala ʻole

A 2021 Ka Nupepa o Proteomics ke aʻo ʻana i ka hopena o ka hoʻokaʻawale kaʻawale ʻana o PBMC ma nā profiles phosphorylation myeloid leukemia acute ʻike ʻia nā loli phosphoproteome ma hope o ka lohi 24-hola, ʻoiai me nā mea paʻa i loaʻa. Hōʻike kēia i ke kumu ʻaʻole he moʻolelo maikaʻi wale nō ka palapala hoʻopaneʻe - he ʻano hoʻokolohua ia e hiki ke hoʻohālikelike i nā hoʻohālikelike hui inā ʻaʻole kūlike..


Nā ʻano ʻokoʻa hoʻonui e hoʻonui a hoʻomāmā i ka walaʻau ʻana ma mua o ka nānā ʻana

ʻO ka hoʻonui ʻana i ka Phosphopeptide ʻaʻole ia he kaʻina neʻe ʻana. ʻO kēlā me kēia ʻāpana o ka hoʻonui - resin chemistry, hoʻouka pH, peptide-a-bead ratio, holoi kaula, a me nā kūlana elution - pili pū me ka heluna kanaka phosphopeptide i hāʻawi ʻia e ka hoʻomākaukau laʻana, a hiki i ka hoʻonui ʻia ʻana o ka hoʻokele maikaʻi ʻole ke hoʻonui i ka ʻokoʻa i hoʻokomo ʻia i luna i ka wā e hūnā ana ma hope o ka ʻikepili MS maʻemaʻe..

Ke Koho Hoonui

ʻO nā kemika nui ʻekolu - IMAC (Fe³⁺, Ga³⁺, Zr⁴⁺, Inā⁴⁺), TiO₂, a me ke kaʻina MOAC (SIMAC) — ʻaʻole hiki ke hoʻololi. Lawe lākou i nā ʻano like ʻole a pane ʻokoʻa i ka walaʻau pre-analytical i loko o ka hui peptide hoʻokomo.

Hana Hoonui

Laulā koho

ʻIke pH

Kūlana Kūlana

ʻIke ʻia ke ʻano hāʻule

Fe/Zr-IMAC

Kiʻekiʻe loa (>97% i nā kūlana kūpono)

Kiʻekiʻe - pono e hoʻouka i ka pH 1.5-2.5

Haʻahaʻa haʻahaʻa i nā peptides multiply-phosphorylated

Hoʻokūkū ka acid non-phosphopeptides inā kiʻekiʻe loa ka hoʻouka ʻana i ka pH

TiO₂

82-99% pili i ka hoʻouka ʻana i nā mea hoʻohui

Maikaʻi - pono ka hoʻouka ʻana i ka waikawa (pH 2–2.5)

Hiki ke kuhi i ka pSer/pThr ma luna o pTyr; multiply-phosphorylated nā ʻano i hoʻonui ʻia i nā lakio bead kiʻekiʻe

Hiki i ka glycolic acid additive ke hōʻemi i ka kikoʻī i kekahi mau protocol

MOAC Sequential (SIMAC)

Ka heluna kanaka palahalaha loa

Hoʻohui i nā ʻanuʻu kaʻina

ʻO ka uhi ākea ākea me nā ʻano hoʻohui

Paʻakikī a me nā poho kumulative; ʻōlelo ikaika ʻia ka prefractionation

ʻIkepili mai a 2015 haʻawina hoʻohālikelike ma PMC i ka hoʻohālikelike ʻana i ka IMAC multi-step a me ka TiO₂ multi-step ua ʻike ʻia ʻekolu pōʻai o kēlā me kēia ala i hopu i ka hapa nui o nā phosphopeptides ʻike ʻia mai nā lysates pūnaewele holoʻokoʻa., me kēlā me kēia pōʻai hou e hāʻawi ana i nā hoʻihoʻi emi. A 2024 hoʻonaʻauao hoʻoponopono ʻōnaehana hōʻike ʻia >16,000 ʻike ʻia nā phosphopeptides mai kahi hoʻonui hoʻokahi i ka wā i hoʻopaʻa ʻia ai ka waikawa glycolic, ka pākēneka elution ammonium hydroxide, peptide-a-bead ratio, manawa paa, a ua hoʻopili pū ʻia ka nui o ka laʻana.

Pono nā ʻāpana ʻelua i ka nānā pono ʻana no ka mea ʻaʻole i hōʻike pinepine ʻia i nā protocol i paʻi ʻia:

Lakiō peptide-a-bead: ʻO ka liʻiliʻi liʻiliʻi e hoʻonui ai i nā peptides phosphorylated; ʻO ka nui o ka resin e hoʻonui i ka paʻa ʻole o nā peptides non-phosphorylated acidic. He loiloi nui o nā hoʻolālā hoʻonui loaʻa ʻo TiO₂ hana maikaʻi loa ma kahi 1:2–1:8 peptide-a-bead ratio (w/w).

Hoʻouka pH: Piʻi nui ka kikoʻī no IMAC a me TiO₂ i ka wā e hoʻouka ʻia ai nā buffer i ka pH 2-2.5 me ka TFA a i ʻole ka acetic acid.. I hoʻokahi hoʻohālikelike POROS-Fe³⁺ a me TiO₂, Ua hoʻomaikaʻi ʻia ka koho mai 12-18% a i 58-60% i ka wā i hoʻohana ʻia ai nā kūlana hoʻouka ʻākaika.

Ke hoʻohana nei i nā Kūlana Phosphopeptide Kūloko ma ke ʻano he ʻīpuka QC

ʻO kekahi o nā mana pre-enrichment pono loa ʻo ia ka spiking sequence-defined nā kūlana peptide phosphorylated ma kahi ʻike i ʻike ʻia ma mua o ka hoʻonui ʻana. ʻO ka hoʻihoʻi ʻana i kēia mau kūlana ma waena o ka hoʻonui ʻana a me nā ʻanuʻu LC-MS e hāʻawi i kahi loiloi kūpono quantitative kūʻokoʻa i ka paʻakikī o ka phosphoproteome endogenous.. Inā hāʻule ka hoʻihoʻi maʻamau ma lalo o kahi paepae i wehewehe ʻia - maʻamau 50-80% ma muli o ka protocol - hiki ke hōʻailona ʻia ka holo hoʻonui ma mua o ka loaʻa ʻana o ka ʻikepili MS., ka pale ʻana i ka manawa mea hana hoʻopau ʻia ma kahi laʻana i hoʻopili ʻia.

No nā kaʻina hana e koi ana i ka hui pū ʻana, kūlike i loko ka hana phosphopeptide maʻamau me ka hoʻomaʻemaʻe HPLC ≥ 95% a me ka hōʻoia ʻana o MS i ka ʻike kikoʻī a me ka hana phosphosite e hāʻawi i ka mea kuhikuhi e pono ai e mālama i kēia puka QC ma nā hoʻokolohua..


Nā ʻāpana LC-MS: ʻO ka pae hope o ka hoʻoponopono mua-analytical

Hoʻohana maʻamau ʻia nā hoʻonohonoho loaʻa ʻana o MS ma ke ʻano he pilikia optimization kūʻokoʻa i ka hoʻomākaukau laʻana. Ma ka hana, pili lākou me ka maikaʻi pre-analytical: Hiki ke ʻae ʻia kahi laʻana i hoʻohaʻahaʻa ʻia ma lalo o nā hoʻonohonoho ʻae ʻae, ʻoiai ʻoi aku ka maikaʻi o kahi laʻana i hoʻomākaukau maikaʻi ʻia me nā kūlana LC like ʻole.

Ka lōʻihi a me ke koho ʻana i ke kolamu

No ka paʻakikī, hoʻohuihui phosphopeptide i hoʻonui ʻia, ʻO ka lōʻihi gradient a me ke kolamu e hoʻoholo ai i ka nui o ka phosphoproteome i hoʻonohonoho ʻia. A 2017 optimization study i paʻi ʻia ma PubMed hōʻike i kahi fritless 50 cm kolamu i hoʻopili ʻia me 1.9 μm mau ʻāpana, holo me kahi gradient LC i hoʻopaʻa ʻia, hāʻawi mai >23,000 phosphopeptides i ka hilinaʻi kiʻekiʻe, e hoike ana a 51% ka hoʻomaikaʻi ʻana i ka hohonu o ke kaʻina ʻana ma luna o nā hoʻonohonoho kolamu pōkole. ʻO ka ʻae like ʻana mai nā haʻawina kikoʻī o nā mea kani e kuhikuhi ana i kahi gradient 90-120 min ma ke ʻano he wahi momona kūpono no nā phosphoproteomics-scale e hoʻohana ana i ka DDA ma nā mea kani Orbitrap kiʻekiʻe..

Nā kolamu hāiki (75 μm ID a i ʻole ka liʻiliʻi) ʻoi aku ka maikaʻi ma muli o ka loaʻa ʻana o ka naʻau electrospray i nā kahe kahe i hoʻemi ʻia i kekahi hapa no ka naʻau o ka ion-suppression sensitivity o phosphopeptides.. A 2024 one-pot microscale workflow study in Nūpepa no ka Proteome Research ua hōʻike ʻia kahi hoʻololi hoʻomaikaʻi 3.6-fold mai kahi a 100 μm i a 25 knm × 75 μm, 1.7 μm C18 kolamu.

Hoʻokaʻawale ʻana a me ka pololei o ka Localization

No ka phosphosite localization, ʻO ke koho ʻana i ke ala ʻāpana e lawe i nā hopena i lalo no ka wehewehe olaola. A 2017 Nūpepa no ka Proteome Research ka loiloi o nā ʻāpana Orbitrap Fusion Ua hoʻoholo ʻo HCD me Orbitrap MS/MS hoʻonā kiʻekiʻe e hāʻawi i nā helu ʻike phosphosite maikaʻi loa, ʻoiai ʻo EThcD e hoʻomaikaʻi i ka hilinaʻi localization per-PSM ma ke kumu kūʻai o kahi pōʻai hana lōʻihi a hōʻemi i ka huina hōʻike ʻike.. ʻO ka manaʻo kūpono: ʻO HCD ka paʻamau kūpono no nā kahe hana ʻike; Pono ʻia ʻo EThcD ke koi ʻia kahi helu liʻiliʻi o nā pūnaewele me nā helu localization pohihihi..

ʻO ka hoʻohaumia ʻana i ka ion metala ma ka ʻōnaehana LC

ʻO kahi kumu i mahalo ʻole ʻia o ka nalowale o ka phosphopeptide i ka wā o ka loiloi LC-MS ʻo ka phosphopeptide-metal complex complex i loko o nā ala kahe metala.. A 2022 ACS Omega ka loiloi ʻana i nā kumu pilikia o ka ʻōnaehana LC ʻike ʻia e hiki i nā ʻāpana LC metala ke hoʻopaʻa i nā phosphopeptides ma mua o ka hiki ʻana i ke kumu ESI, me ka hoʻohui ʻana o EDTA i ka mea hoʻonā hāpana i ʻike ʻia ma ke ʻano he countermeasure kūpono ma ka pale ʻana i ka hoʻokumu paʻakikī. He kūpono kēia no nā hale hana ʻaʻole hoʻohana i nā ʻōnaehana LC bio-inert.


He Mana Hoʻoponopono Pre-Analytical Control Framework: Papa Hoʻoholo i kēlā me kēia pae

Hoʻonohonoho ka papa hana ma lalo nei i nā ʻano hoʻololi pre-analytical i hōʻike ʻia ma luna i loko o kahi kaʻina puka. Pono e loiloi ʻia kēlā me kēia pae ma mua o ka hele ʻana i ka pae aʻe, me nā ʻokoʻa i kākau ʻia ma ke ʻano he hoʻokolohua covariates ma mua o ka hoʻolei ʻia ʻana.

Ke kahua

Hoʻololi

Palapala ʻae

Hana inā hāʻule

ʻOhi laʻana

Ischemia wela / lohi ohi

≤ 20 min (kikokiko); ≤ 2 h (koko/PBMC)

Haʻalele a hae paha; palapala manawa ischemia like covariate

Hoʻopaʻa / hoʻokūpaʻa

Ka wela ma ka hana mua

0–4°C a puni

E hana hou i ka hōʻiliʻili ʻana inā ʻae ʻia ka protocol; mai hoʻohana i ka laʻana i hoʻohālikelike ʻia me ka ʻole o ka hōʻike

Lysis pale

Ka uhi ʻana o ka mea hoʻopaʻa phosphatase

Uhi ka cocktail i ka serine/threonine a me ka tyrosine phosphatases

Hoʻoponopono hou i ka pale; hōʻoia me ka spike-recovery o nā kūlana phosphopeptide

ʻO ka ʻai ʻana

Ka lawe ʻana i loko o ka digest

Ua hōʻike ʻia ka ʻike ʻana o ka inhibitor ma lalo o ka paepae inhibition trypsin

Depaʻa ma mua o ka ʻai ʻana; hōʻoia i ka uhi peptide ma kahi laʻana

Hoʻokomo waiwai

Ka helu peptide

Ua lawa ka nui komo no ka lakene resin i kohoia

Hoʻoponopono i ka nui resin a hoʻemi paha i ka ratio bead; ʻaʻole ʻoi aku ma mua o ka pae peptide-to-bead i hōʻoia ʻia

Hoʻokō waiwai

Hoʻouka i ka pH pale

ʻO ka pH 2.0–2.5 i hoʻopaʻa ʻia me ka hōʻailona a i ʻole ka mika pH

Hana hou i ka hoʻouka ʻana; mai hoʻomau i ka pH ma waho o kēia pae

Hoʻonui QC

Hoʻihoʻi maʻamau kūloko

≥ 50% ka hoʻihoʻi ʻana i nā kūlana phosphopeptide spiked

Pūʻulu hae; hoʻonui hou inā lawa ka laʻana; hōʻike i ka hoʻihoʻi ʻana ma nā ʻano hana

LC-MS

ʻO ke kaomi kua hope a me ke ʻano kiʻekiʻe

Ma loko o ± 15% o ka holo kumu; nā piko phosphopeptide symmetrical

Hoʻololi a hoʻoponopono hou i ke kolamu; e nānā i ka ʻelemakule a i ʻole ke kolamu

LC-MS

Ka helu helu hoʻonaʻauao phosphosite

≥ 75% o phosphopeptides me ka papa I localization (helu ≥ 0.75)

E nānā i nā kikoʻī hoʻonui a me ka calibration mea hana

ʻAʻole hoʻololi kēia ʻano hana i ka hoʻomohala ʻana - hāʻawi ia i ka hoʻolālā loiloi i loko o kahi e hoʻoholo ʻia ai nā hoʻoholo hoʻomohala ʻana.


He Pepa Palapala QC Mākaukau

Hiki ke hoʻohana ʻia ka papa ma kēlā me kēia ʻanuʻu i ka wā e hoʻopaʻa ʻia ai kēlā me kēia waiwai koʻikoʻi i kēlā me kēia pūʻulu. Hoʻolālā ʻia ka papa helu ma lalo nei e kope pololei ʻia i loko o kahi puke keʻena hana a i ʻole ka ʻōnaehana mooolelo uila, me hoʻokahi kolamu no ka laʻana a me kahi kahua hoʻokaʻawale palapala:

Kahua e hoʻopaʻa

Laʻana Waiwai

ʻaʻe / Nā memo

Laʻana ID a me ka matrix

ʻāpaʻa, hou-hau Hana ʻia ʻo Peptide

—

Ischemia wela / lohi ohi

14 min

i loko o ka palena

Ka manawa ischemia anu

22 min

i loko o ka palena

Ka wela ma ka hana mua

4°C

—

Lysis pale + helu hailona inhibitor

PhosSTOP hailona ####; pūʻulu NaF ####

—

ʻO ka wehe ʻana i ka mea pale ma mua o ka ʻai ʻana (Y/N)

Y

—

Kemika hoʻonui a me ka pūʻulu bead

TiO₂, hailona ####

—

Lakiō peptide-a-bead

1:4 (w/w)

—

Hoʻouka i ka pH pale

2.2

—

Hoʻihoʻi maʻamau kūloko (%)

72%

maluna 50% puka pā

Papa I ka helu wahi (%)

81%

—

ʻO ka hoʻopaʻa ʻana i kēia mau kahua e hoʻohuli i ka anga i kahi moʻolelo maikaʻi e hana hou ʻia a hiki ke hoʻopaʻa ʻia nā deviations ma mua o ka ʻike ʻole ʻia..

Mai ka Framework a hiki i ka Reproducible Conclusions

ʻO ka pahuhopu o ka mana pre-analytical ʻaʻole ia ka perfectionism methodological. ʻO ia ka hiki ke hoʻohālikelike i nā mokuʻāina phosphoproteome ma waena o nā laʻana, nā manawa manawa, a i ʻole nā ​​hui lapaʻau a me nā ʻano ʻokoʻa i ʻike ʻia i ka biology ma mua o ka lawelawe ʻana i nā mea kiʻi. He hoʻolālā i kūkulu ʻia ma luna o nā pae ʻae ʻae ʻia, palapala kuhi hewa, a me nā kūlana kūloko e hoʻohuli i ka phosphoproteomic workflow mai kahi hilinaʻi paʻa i ka mālama ʻana i ka protocol i kahi moʻolelo maikaʻi loa..

ʻO ka hoʻohālikelike ʻana i nā SOP ma nā ʻano laʻana - a ma waena o ka poʻe e hōʻiliʻili ana i nā laʻana i kahi noiʻi multicenter - pono e wehewehe ʻia kēlā me kēia ʻāpana koʻikoʻi i ka papa ma luna., anaia, a hoʻopaʻa ʻia, ʻaʻole i paipai wale ʻia. Ka manawa ischemia anu, helu hailona phosphatase inhibitor, hoʻomāhuahua ʻana i nā ʻāpana bead, a ʻo nā waiwai hoʻihoʻi maʻamau maʻamau e ʻike ʻia ma ka ʻāpana hana o kēlā me kēia noiʻi phosphoproteomics e koi ana i ka pili o ke kino..

No ke kūkulu ʻana a i ʻole ka loiloi ʻana i nā panela kuhikuhi phosphopeptide, MOL Changes peptide CRO lawelawe hiki ke kākoʻo i ka synthesis a me ke ʻano o nā kūlana phosphopeptide kikoʻī kikoʻī me ka palapala HPLC a me MS CoA piha., e hāʻawi ana i ke kumu waiwai no ka hoʻopaʻa ʻana i ka QC ma waena o nā hoʻokolohua.


No keia alakai a me na mea kakau

Ua hoʻomākaukau ʻia kēia ʻatikala e ka hui ʻenehana MOL Changes, ʻO kāna hana e pili ana i ka synthesis peptide maʻamau, hoʻololi phosphopeptide, a me ke ano analytical (HPLC a me MS) no ka noiʻi a me nā noi CRO. Hoʻopili ke kāʻei i hōʻike ʻia ma ʻaneʻi i nā palapala hoʻomākaukau hoʻohālike i paʻi ʻia ma mua o ka hōʻike ʻana i ka ʻikepili kumu hou; kahi e wehewehe ai mākou i nā paepae hana, hōʻike mākou inā mai nā kumu i loiloi ʻia e nā hoa a i ʻole nā ​​​​kumuhana hoʻomaʻamaʻa i kā mākou synthesis a me nā kahe hana QC..

No ka mālama pono ʻana i kēia alakaʻi, ua loiloi ʻia i loko no ke kūlike me ka hana hoʻomākaukau laʻana phosphoproteomic maʻamau. ʻO ka poʻe heluhelu e koi ana i nā hōʻoia o ka pae kākau, nā hui hui, a i ʻole ka mea loiloi ʻepekema i kapa ʻia no nā kumu kuhi noi i ka pūʻolo ʻikepili ʻenehana, i loaʻa nā kikoʻī loiloi a me nā palapala kikoʻī he nui.

Nānā: Ke hoʻopaʻa ʻia nei nā laina o ka mea kākau pilikino a me nā pilina pili; e hōʻano hou ʻia ka ʻāpana ma luna me nā inoa inoa.

ʻO ka hoʻopaʻapaʻa no ka hoʻopaʻi pre-analytical i ka hopena he hoʻopaʻapaʻa no ka hilinaʻi ʻepekema. ʻAʻole hiki ke wehewehe pono ʻia nā ʻikepili Phosphoproteomics ʻaʻole hiki ke ʻike ʻia i kahi moʻolelo hoʻohālike i hoʻomalu ʻia - ʻaʻole no ka mea ua wahaheʻe ka spectrometer., akā, no ka mea, ʻo ka hōʻailona olaola āna i ana ai, ua hui pū ʻia me ka biology a me ka lawelawe ʻana. E kūkulu i ke kaʻa ma mua o ka unuhi ʻana. Ke hilinaʻi nei kāu mau hopena.


I kā mākou synthesis a me ka hana QC e hāʻawi ana i nā kūlana phosphopeptide, ʻike mau mākou i ka lihi kūpono o kēia mau ʻike: ʻokoʻa ka hoʻihoʻi ʻana i nā maʻamau spiked me nā kikoʻī hoʻoponopono i wehewehe ʻia ma luna, ʻo ia ke kumu e mālama ai mākou i ka mōʻaukala laʻana i hoʻopaʻa ʻia me he mea hiki ʻole ke hoʻokaʻawale ʻia mai ka hopena analytical. Ma mua o ka hāʻule hoʻokahi, ʻO ke ʻano hoʻi hou ʻana he lohi lohi o ka maikaʻi o ka hōʻailona e maʻalahi ke nalo a hiki i ka pau ʻana o kahi hoʻohālikelike pūʻulu. Ua hoʻonohonoho mākou i nā koina ʻae i kēia ʻatikala e hōʻike i kēlā ʻoiaʻiʻo hana, a paipai mākou i nā hui e hoʻopaʻa inoa i ka waiwai hoʻihoʻi kumu no kā lākou protocol maʻamau i ʻike ʻia kekahi kahe ma mua o ka hoʻopau ʻana i kahi hoʻohālikelike..

Mākaukau e kūkākūkā i nā kikoʻī peptide kuhikuhi no kāu kaila hana QC phosphoproteomics?

Nā kuhikuhi

  1. No ke aha i paʻakikī ai ka phosphoproteomics - Molecular BioSystems (2015). https://pubs.rsc.org/en/content/articlehtml/2015/mb/c5mb00024f

  2. Hoʻoponopono i ka tyrosine phosphorylation i loko o ka membrane cell T i hoʻokaʻawale ʻia e ka pale ʻana i nā protein tyrosine phosphatases - PubMed (1998). https://pubmed.ncbi.nlm.nih.gov/9712039/

  3. ʻO Tyrosine phosphorylation a me Src family kinases e hoʻomalu i ka keratinocyte cell-cell adhesion - PMC (1998). https://pmc.ncbi.nlm.nih.gov/articles/PMC2132783/

  4. Nā hōʻike no ka tyrosine phosphorylation i loko o nā pūnaewele kanaka - PMC (2019). https://pmc.ncbi.nlm.nih.gov/articles/PMC7379381/

  5. Nā hoʻololi phosphoproteome unspecific i hoʻoulu ʻia e ka ischemia anuanu - Nūpepa no ka Proteome Research (2013). https://pubs.acs.org/doi/abs/10.1021/pr400451z

  6. Hōʻike Phophoepitope a me ka manawa-i-hoʻopaʻa i ka kiko FFPE - Imi Keena Hana (2014). https://www.nature.com/articles/labinvest2014139

  7. ʻO ka ischemia anuanu ma ka ʻiʻo ʻiʻo: nā hopena no ka nānā ʻana i ka phosphostatus - PMC (2021). https://pmc.ncbi.nlm.nih.gov/articles/PMC7893972/

  8. ʻO ka protocol hoʻomākaukau laʻana phosphoproteomic maʻamau - PMC (2012). https://pmc.ncbi.nlm.nih.gov/articles/PMC3332032/

  9. Olsen et al., Nā ʻenehana hoʻonui i hoʻohana ʻia i ka phosphoproteomics - PMC (2011). https://pmc.ncbi.nlm.nih.gov/articles/PMC3418503/

  10. ʻO ka hoʻomākaukau hoʻomākaukau ʻana o Phosphoproteomics e pili ana i ka wehewehe ʻana i ka biological - PMC (2021). https://pmc.ncbi.nlm.nih.gov/articles/PMC8699897/

  11. Hoʻohālikelike i ka IMAC multi-step a me ka hoʻonui ʻana i ka TiO₂ multi-step — PMC (2015). https://pmc.ncbi.nlm.nih.gov/articles/PMC4766865/

  12. ʻO ka hoʻonui ʻia ʻana o ka TiO₂ phosphopeptide enrichment - PMC (2024). https://pmc.ncbi.nlm.nih.gov/articles/PMC11087715/

  13. Ka loiloi nui o nā hoʻolālā hoʻonui phosphopeptide - PMC (2016). https://pmc.ncbi.nlm.nih.gov/articles/PMC4849134/

  14. Hoʻonui ka hoʻouka ʻana i ka ʻakika i ka koho IMAC a me TiO₂ - PubMed (2012). https://pubmed.ncbi.nlm.nih.gov/22406350/

  15. ʻO ka loiloi LC kolamu lōʻihi no ka phosphoproteomics - PubMed (2017). https://pubmed.ncbi.nlm.nih.gov/28634120/

  16. Hoʻokahi-pot microscale phosphoproteomic workflow - Nūpepa no ka Proteome Research (2024). https://pubs.acs.org/doi/10.1021/acs.jproteome.3c00862

  17. Ka loiloi o nā ʻāpana ʻāpana no ka localization phosphosite - Nūpepa no ka Proteome Research (2017). https://pubs.acs.org/doi/10.1021/acs.jproteome.7b00337

  18. ʻO ka hoʻohaumia ʻana o ka ʻōnaehana LC a me ka nalowale o ka phosphopeptide - ACS Omega (2022). https://pubs.acs.org/doi/10.1021/acsomega.2c05616

  19. ʻIke liʻiliʻi e pili ana i ka hoʻomākaukau ʻana no ka Phosphoproteomics — Nature Precedings (2009). https://www.nature.com/articles/npre.2009.3131.1

E kelepona i ka hui ʻenehana MOL Changes ma o kā mākou lawelawe peptide ʻaoʻao no ke noi ʻana i kahi kūkākūkā ʻenehana a i ʻole pūʻolo ʻikepili kikoʻī nui.

Bingyan Gao

Bingyan Gao

Mea Hana Pono a me Analytical Kaʻike kumu: ʻO ka hoʻokaʻawale ʻana a me ka ʻike ʻana i nā ʻano haumia, Hoʻomohala ʻano hana HPLC/MS, ka hoʻomaʻemaʻe kiral, a me ka hoʻokō ʻana i nā pharmacopoeias honua.

Pilikino: ʻO Bingyan Gao ka "puka kiaʻi hope" o ka maʻemaʻe peptide a me ka maikaʻi. Maikaʻi ʻo ia i ka hoʻohana ʻana i nā mea analytical kiʻekiʻe kiʻekiʻe a loea i ka hoʻomohala ʻana i nā ʻano hoʻokaʻawale chromatographic maʻamau no nā peptides hoʻololi paʻakikī.. Ua hoʻokumu ʻo ia i kahi ʻōnaehana hoʻomaʻemaʻe pono ʻole e hōʻoia i ka maʻemaʻe o ka huahana 99% a i ʻole kiʻekiʻe aʻe akā ʻike pono a hoʻopau i nā ʻano haumia i hiki ke hoʻoulu i ka immunogenicity. Me ka hoʻomaopopo hohonu ʻana i nā koi hoʻoponopono FDA a me EMA no nā lāʻau peptide, hōʻoia ʻo ia ʻo kēlā me kēia pūʻulu i hoʻokuʻu ʻia mai ka hale hana e hele pū ʻia me kahi palapala hōʻoia o ka ʻike ʻana (COA).

ʻIke ʻia & Nā alakaʻi hoʻoponopono
Nānā ʻia e: Ka poe akamai kumuhana
Kaʻana like i kēia ʻatikala
Home Huli Whatsapp Nā lawelawe Huahana